SS Innovations International, Inc. (SSII) · Oct 13, 2026 · Other events
FDA response submitted — Response submitted October 5, 2026
SS Innovations’ FDA response adds final validation data for Mantra, moving its U.S. 510(k) review forward—but it is not FDA clearance.
SS Innovations is an early-stage surgical-robotics company commercializing the SSi Mantra in India and international markets while pursuing U.S. regulatory clearance. Recent company materials put the FDA review on a Q4 2026–Q1 2027 timeline after an additional-information request received in April 2026.
The filing confirms progress, not approval. SS Innovations submitted its response to the FDA’s additional-information request on October 5, including final data from an expanded human clinical and human-factors validation study. That removes a defined regulatory-work item, but the filing does not say the FDA accepted the response, cleared the device, or set a decision date.
The added evidence is meaningful but narrow in scope. The response also includes final data from a bridging study completed in August 2026 in Colombia. The 510(k) submission now covers an initial cholecystectomy indication, rather than the broader multi-specialty opportunity emphasized in earlier company materials.
Versus expectations, this is largely an execution milestone. The company had already indicated that it expected to respond to the FDA during October 2026, so the direction was known; the new information is that the response was filed with the requested validation work completed. There is no published earnings-style consensus to beat, and no clearance announcement here.
Bottom line: This keeps the U.S. regulatory process moving and supports the existing timetable, but it does not materially de-risk the final FDA decision yet. The core commercial story remains contingent on 510(k) clearance.
FDA decision on 510(k), targeted Q4 2026–Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!